John T. Huggins

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

Bruno Crestani, John T. Huggins, Mitchell Kaye et al. · The Lancet Respiratory Medicine · 2018 · 235 citations

Antifibrotic Therapy, Open-label Extension Study, Idiopathic Pulmonary Fibrosis +5

Management of Pneumothorax in Lymphangioleiomyomatosis

Khalid F. Almoosa, Jay H. Ryu, José L. Méndez et al. · CHEST Journal · 2006 · 155 citations

Pneumothorax, Surgical Pathology, Pathology +4

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

Kevin R. Flaherty, Charlene D. Fell, John T. Huggins et al. · European Respiratory Journal · 2018 · 129 citations · Full text

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

Wim Wuyts, Martin Kolb, Susanne Stowasser et al. · Lung · 2016 · 120 citations · Full text

Pleural Effusions in a Series of 181 Outpatients With Sarcoidosis

John T. Huggins, Peter Doelken, Steven A. Sahn et al. · CHEST Journal · 2006 · 119 citations

Pleural Effusions, Emergency Medicine, Pleural Effusion +1